## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.27 indicates fundamental undervaluation. Caution: declining volume (52% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($136.90)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Neurocrine Biosciences, Inc. $NBIX Shares Sold by Rice Hall James & Associates LLC**
- Source: MarketBeat | 20251227T120938 | Somewhat-Bullish | Relevance: 100%
- Rice Hall James & Associates LLC reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.2% in the third quarter of 2025, selling 8,917 shares. Despite this, Neurocrine posted a strong Q3 performance, exceeding EPS and revenue expectations. Analysts remain largely bullish on NBIX, with several firms raising price targets and a consensus "Moderate Buy" rating.

**2. Neurocrine Biosciences director sells shares worth $269,167**
- Source: MSN | 20251226T190933 | Somewhat-Bearish | Relevance: 100%
- This article reports that a director at Neurocrine Biosciences sold shares of the company's stock valued at $269,167. This transaction represents an insider selling activity, which can sometimes be monitored by investors for insights into a company's prospects. Specific details regarding the director's identity or the number of shares sold are not provided in this snippet.

**3. Swedbank AB Has $76.83 Million Position in Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20251225T110938 | Somewhat-Bullish | Relevance: 100%
- Swedbank AB increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.7% in Q3, now holding 547,329 shares valued at $76.83 million. Other institutional investors like JPMorgan Chase & Co. and Norges Bank also hold significant positions, contributing to 92.59% institutional ownership. Neurocrine Biosciences reported strong Q3 earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus rating with an average price target of $175.25.

**4. Neurocrine Biosciences (NBIX) Stock News: Brighton Jones Raises Stake to $1.43M**
- Source: Eudaimonia and Co | 20251224T130900 | Somewhat-Bearish | Relevance: 100%
- Brighton Jones LLC significantly increased its stake in Neurocrine Biosciences (NBIX) by 266.2% in Q3 2025, now holding 10,216 shares worth $1.43 million, despite NBIX shares facing headwinds from disappointing Phase 3 clinical trial results for valbenazine in dyskinetic cerebral palsy. Analysts maintain a 'Strong Buy' rating for NBIX, citing robust earnings despite the clinical setback and stock fluctuations.

**5. Brighton Jones LLC Has $1.43 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20251224T090900 | Bullish | Relevance: 100%
- Brighton Jones LLC significantly increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 266.2% in Q3, now holding 10,216 shares valued at $1.43 million. This comes after Neurocrine Biosciences reported strong Q3 results, beating EPS and revenue expectations, leading to multiple analyst price target increases and a "Moderate Buy" consensus. Despite institutional ownership of 92.59%, insiders have sold a considerable number of shares in the past three months.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | HC Wainwright & | $198 | $168 | +18% |
| 2025-12-12 | Mizuho | $175 | $146 | +20% |
| 2025-12-11 | Stifel | $188 | $183 | +3% |
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | HC Wainwright & | main | Buy |
| 2025-12-12 | Mizuho | main | Neutral |
| 2025-12-11 | Stifel | main | Buy |
| 2025-12-08 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 10 ($2.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +13%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 15.8x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (5 raises, avg +13%). Insider selling cluster ($3.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.5B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 15.8 |
| Current P/E | 21.0 |
| YoY Growth | 32.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 8.3pp (needs >4.0% for momentum thesis). AM_20 at -3.4% indicates price below own 20MA trend. Underperforming sector by 4.9pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-0.91), momentum weakening. RSI neutral at 45. Volume at 52% of 20MA suggests lack of conviction. OFD pattern: -STL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.32% (CS: 12) | Weak |
| RSI_14 | 44.8 | Neutral |
| MACD Histogram | -0.91 | Bearish |
| vs SMA20 | 0.966x | Below |
| vs SMA50 | 0.991x | Below |
| vs SMA200 | 1.114x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $145.26
- **Stop Loss:** $136.90 (5.8% risk)
- **Target:** $161.98 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 157
- **Position Value:** $22,805.82
- **Portfolio %:** 22.81%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*